Lopata Andreas L, Lehrer Samuel B
RMIT University, Bundoora West Campus, Melbourne, Victoria, Australia.
Curr Opin Allergy Clin Immunol. 2009 Jun;9(3):270-7. doi: 10.1097/ACI.0b013e32832b3e6f.
Seafood plays an important role in human nutrition worldwide, sustained by international trade of a variety of new seafood products. Increased production and consumption have resulted in more frequent reports of adverse reactions, highlighting the need for more specific diagnosis and treatment of seafood allergy. This review discusses recent literature in this field.
The most recent prevalence data from Asia highlight seafood as a significant sensitizer in up to 40% of children and 33% of adults. Furthermore, the demonstration of species-specific sensitization to salt-water and fresh-water prawns and processed prawn extract should improve diagnosis. Studies on humans demonstrated for the first time that biologically active fish allergens can be detected in serum samples as early as 10 min after ingestion. These studies highlight that minute amounts of ingested seafood allergens can quickly trigger allergic symptoms; also, inhaled airborne allergens seem to induce sensitization and reactions. In the past 2 years, over 10 additional seafood allergens have been characterized. Allergen-specific detection assays in food products are available for crustacean tropomyosin; however, many specific mollusk and some fish allergens are not readily identified.
Although cross-reactivity between crustacean and mollusks as well as mites is demonstrated, the often poor correlation of IgE reactivity and clinical symptoms calls for more detailed investigations. The recent development of hypoallergenic parvalbumin from carp could form the basis for safer vaccination products for treatment of fish allergy. Molecular characterization of more universal marker allergens for the three major seafood groups will improve current component-resolved clinical diagnosis and have a significant impact on the management of allergic patients, on food labeling and on future immunotherapy for seafood allergy.
海鲜在全球人类营养中发挥着重要作用,这得益于各种新型海鲜产品的国际贸易。产量和消费量的增加导致不良反应报告更加频繁,凸显了对海鲜过敏进行更精准诊断和治疗的必要性。本综述讨论了该领域的最新文献。
来自亚洲的最新患病率数据表明,海鲜是高达40%的儿童和33%的成年人的重要致敏原。此外,对咸水虾、淡水虾和加工虾提取物的种特异性致敏的证明应有助于改善诊断。对人类的研究首次表明,摄入后10分钟即可在血清样本中检测到具有生物活性的鱼类过敏原。这些研究强调,摄入微量海鲜过敏原可迅速引发过敏症状;此外,吸入空气中的过敏原似乎也会引发致敏和反应。在过去两年中,又鉴定出了10多种海鲜过敏原。食品中过敏原特异性检测方法可用于检测甲壳类原肌球蛋白;然而,许多特定软体动物和一些鱼类过敏原不易识别。
尽管已证明甲壳类动物与软体动物以及螨虫之间存在交叉反应,但免疫球蛋白E反应性与临床症状之间通常相关性较差,这需要进行更详细的研究。最近从鲤鱼中开发出低敏性小清蛋白,可为治疗鱼类过敏的更安全疫苗产品奠定基础。对三大类海鲜更通用的标记性过敏原进行分子表征,将改善当前基于成分的临床诊断,并对过敏患者的管理、食品标签以及未来海鲜过敏免疫疗法产生重大影响。